Desmocollin-3: A new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung

Modern Pathology

Volumn 22, Issue 5, 2009, Pages 709-717

  Monica, Valentina ^a   Ceppi, Paolo ^a   Righi, Luisella ^a   Tavaglione, Veronica ^a   Volante, Marco ^a   Pelosi, Giuseppe ^b   Scagliotti, Giorgio V ^a   Papotti, Mauro ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Desmocollin 3; Diagnosis; Large cell carcinoma; Squamous differentiation

Indexed keywords

DESMOCOLLIN; DESMOCOLLIN 3; MUCIN; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER THERAPY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYTOLOGY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; TISSUE DIFFERENTIATION; UNDIFFERENTIATED CARCINOMA;

CARCINOMA, LARGE CELL; CARCINOMA, SQUAMOUS CELL; DESMOCOLLINS; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 67349207430     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.30     Document Type: Article

References (24)

1. Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008;3:1468-1481.
2. Travis WD, Colby TV, Corrin B. Histological Typing of Lung and Pleural Tumours. WHO International Histological Classification of Tumours, 3rd edn. Springer: Berlin, 1999.
3. Travis WD, Brambilla E, Mü ller-Hermelink HK, et al. World Health Organisation Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart, 4th edn. IARC Press: Lyon, 2004.
4. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
5. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
6. Aita M, Fasola G, Defferrari C, et al. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2008;68:183-196.
7. Downey P, Cummins R, Moran M, et al. If it's not CK5/6 positive, TTF-1 negative it's not a squamous cell carcinoma of lung. APMIS 2008;116:526-529.
8. Fabbro D, Di Loreto C, Stamerra O, et al. TTF-1 gene expression in human lung tumours. Eur J Cancer 1996;32A:512-517.
9. Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 2003;34:597-604.
10. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol 2001;25: 363-372.
11. Nonaka D, Chiriboga L. Basal cell differentiation in lung adenocarcinoma. [abstract]. Mod Pathol 2008; 21S:348A.
12. Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 2004;122:884-893.
13. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
14. Hayes DN, Monti S, Parmigiani G, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006;24:5079-5090.
15. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-827.
16. Angulo B, Suarez-Gauthier A, Lopez-Rios F, et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008;214:347-356.
17. Fukuoka J, Dracheva T, Shih JH, et al. Desmoglein 3 as a prognostic factor in lung cancer. Hum Pathol 2007;38:276-283.
18. Legan PK, Yue KK, Chidgey MA, et al. The bovine desmocollin family: a new gene and expression patterns reflecting epithelial cell proliferation and differentiation. J Cell Biol 1994;126:507-518.
19. Lazzaro D, Price M, de Felice M, et al. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development 1991;113:1093-1104.
20. Katzenstein AL, Prioleau PG, Askin FB. The histologic spectrum and significance of clear-cell change in lung carcinoma. Cancer 1980;45:943-947.
21. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596.
22. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med 2006;355: 983-991.
23. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006;17:1818-1825.
24. Edwards SL, Roberts C, McKean ME, et al. Preoperative histological classification of primary lung cancer: accuracy of diagnosis use of the non-small cell category. J Clin Pathol 2000;53:537-540.